A phase I trial of selinexor, ruxolitinib and methylprednisolone for patients with relapsed/refractory multiple myeloma
Sponsor: Karyopharm
Protocol Number: KPT-IST-391
Start Date: Pending IND/IRB Approval
Not active
(Link not available as study is not submitted to FDA)